Categories: Infectious diseases, Skin diseases

Aliases & Classifications for Vaccinia

MalaCards integrated aliases for Vaccinia:

Name: Vaccinia 12 44 15 71


External Ids:

Disease Ontology 12 DOID:3298
MeSH 44 D014615
SNOMED-CT 67 111852003
UMLS 71 C0042214

Summaries for Vaccinia

Disease Ontology : 12 A viral infectious disease that results in infection, located in skin, has material basis in Vaccinia virus, which is used as a live vaccine against smallpox. The virus is transmitted by contact with the vaccination site before it has healed, or transmitted by fomites that have been contaminated with live virus from the vaccination site. The infection has symptom rash, has symptom fever, and has symptom body aches.

MalaCards based summary : Vaccinia is related to variola major and herpes simplex, and has symptoms including fever, rash and body aches. An important gene associated with Vaccinia is VRK1 (VRK Serine/Threonine Kinase 1), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Sorafenib and Angiogenesis Inhibitors have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and prostate, and related phenotype is hematopoietic system.

Wikipedia : 74 Vaccinia virus (VACV or VV) is a large, complex, enveloped virus belonging to the poxvirus family. It... more...

Related Diseases for Vaccinia

Diseases related to Vaccinia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 400)
# Related Disease Score Top Affiliating Genes
1 variola major 32.2 DUSP3 CYB5R3
2 herpes simplex 31.5 IRF3 IFNA1 EIF2S1 EIF2AK2
3 monkeypox 31.5 IRF3 IFNA1 CYB5R3
4 stomatitis 31.2 IL2 IFNA1 EIF2AK2 CSF2
5 measles 31.1 IRF3 IL2 IFNA1 EIF2AK2
6 influenza 31.1 IRF3 IFNA1 EIF2S1 EIF2AK2
7 immune deficiency disease 31.1 IL2 IFNA1 ERVW-1 EIF2AK2 CSF2 BANF1
8 japanese encephalitis 30.9 IRF3 IL2 IFNA1
9 newcastle disease 30.9 IRF3 IFNA1 EIF2S1 EIF2AK2
10 mumps 30.7 IL2 IFNA1 EIF2AK2
11 exanthem 30.7 IL2 IFNA1 CSF2
12 lassa fever 30.6 IRF3 IFNA1 ERVW-1
13 viral infectious disease 30.5 IRF3 IL2 IFNA1 ERVW-1 EIF2S1 EIF2AK2
14 ebola hemorrhagic fever 30.3 IRF3 IFNA1 ERVW-1
15 st. louis encephalitis 30.1 IFNA1 ERVW-1
16 acquired immunodeficiency syndrome 30.0 IL2 IFNA1 CSF2
17 human immunodeficiency virus infectious disease 30.0 IL2 IFNA1 ERVW-1 CSF2
18 hypereosinophilic syndrome 29.5 IL2 IFNA1 CSF2
19 cowpox 11.1
20 smallpox 11.1
21 post-vaccinal encephalitis 11.0
22 human immunodeficiency virus type 1 10.6
23 rabies 10.6
24 encephalitis 10.5
25 severe combined immunodeficiency 10.4
26 dermatitis 10.4
27 pontocerebellar hypoplasia, type 1a 10.4 VRK2 VRK1
28 microphthalmia with limb anomalies 10.4 IRF3 IFNA1 EIF2AK2
29 chickenpox 10.4
30 west nile fever 10.4 IRF3 IFNA1 ERVW-1
31 skin sarcoidosis 10.4 IL2 IFNA1
32 herpangina 10.4 IRF3 IL2 IFNA1
33 engraftment syndrome 10.4 IFNA1 CSF2
34 coronavirus infectious disease 10.4 IRF3 IFNA1 ERVW-1
35 dermatitis, atopic 10.3
36 human herpesvirus 8 10.3 IFNA1 EIF2AK2
37 cytokine deficiency 10.3
38 superficial basal cell carcinoma 10.3 IL2 IFNA1
39 melanoma 10.3
40 avian influenza 10.3
41 molluscum contagiosum 10.3
42 argentine hemorrhagic fever 10.3 IFNA1 ERVW-1
43 hepatitis c virus 10.3
44 colon adenocarcinoma 10.3
45 conjunctival disease 10.3 IL2 IFNA1 CSF2
46 fibroma 10.3
47 allergic disease 10.3
48 glioma 10.3
49 glial tumor 10.3
50 lymphocytic choriomeningitis 10.3

Graphical network of the top 20 diseases related to Vaccinia:

Diseases related to Vaccinia

Symptoms & Phenotypes for Vaccinia


  • fever
  • rash
  • body aches

MGI Mouse Phenotypes related to Vaccinia:

# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.4 AZI2 BTRC CSF2 DUSP3 EIF2AK2 EIF2S1

Drugs & Therapeutics for Vaccinia

Drugs for Vaccinia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 102)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Sorafenib Approved, Investigational Phase 3 284461-73-0 216239 406563
2 Angiogenesis Inhibitors Phase 3
3 Anticonvulsants Phase 3
4 Neurotropin Phase 3
5 Analgesics Phase 3
6 Protein Kinase Inhibitors Phase 3
7 Iron-Dextran Complex Phase 3
Cetuximab Approved Phase 1, Phase 2 205923-56-4 56842117 2333
Oxaliplatin Approved, Investigational Phase 1, Phase 2 61825-94-3 5310940 9887054 6857599 43805
Irinotecan Approved, Investigational Phase 1, Phase 2 97682-44-5, 100286-90-6 60838
Testosterone Approved, Investigational Phase 2 58-22-0 6013
Flutamide Approved, Investigational Phase 2 13311-84-7 3397
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
Heparin Approved, Investigational Phase 1, Phase 2 9005-49-6 772 9812414
Bicalutamide Approved Phase 2 90357-06-5 56069 2375
Goserelin Approved Phase 2 65807-02-5 47725 5311128
Aldesleukin Approved Phase 2 110942-02-4, 85898-30-2
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
BCG vaccine Approved, Investigational Phase 1, Phase 2
nivolumab Approved Phase 1, Phase 2 946414-94-4
Cemiplimab Approved, Investigational Phase 1, Phase 2 1801342-60-8
Flucytosine Approved, Investigational Phase 1, Phase 2 2022-85-7 3366
Bevacizumab Approved, Investigational Phase 1, Phase 2 216974-75-3
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
Aluminum hydroxide Approved, Investigational Phase 2 21645-51-2
Emtricitabine Approved, Investigational Phase 2 143491-57-0 60877
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
Tenofovir Experimental, Investigational Phase 2 147127-20-6 464205
32 Molgramostim Investigational Phase 2 99283-10-0
33 topoisomerase I inhibitors Phase 1, Phase 2
34 Anti-Retroviral Agents Phase 2
35 Hormones Phase 2
36 Hormone Antagonists Phase 2
37 Androgen Antagonists Phase 2
38 Antineoplastic Agents, Hormonal Phase 2
39 Brewer's Yeast Phase 2
40 Antimitotic Agents Phase 2
41 Tubulin Modulators Phase 2
42 Heptavalent Pneumococcal Conjugate Vaccine Phase 2
43 Immunosuppressive Agents Phase 2
44 Antirheumatic Agents Phase 2
45 Alkylating Agents Phase 2
46 Antithrombins Phase 1, Phase 2
47 Serine Proteinase Inhibitors Phase 1, Phase 2
48 Heparin Cofactor II Phase 1, Phase 2
49 Tissue Plasminogen Activator Phase 1, Phase 2
50 Antithrombin III Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 152)
# Name Status NCT ID Phase Drugs
1 Phase 4 Study of Speeda® Rabies Vaccinia That Use for Protection the Crowd Bitten by Animals to Three-level Completed NCT01827917 Phase 4
2 A Special Access Program for the Prophylactic Vaccination With IMVAMUNE® for Personnel Working Directly With or in the Vicinity of Replicating Vaccinia Virus Completed NCT03472014 Phase 4
3 Vaccinia Vaccination (ACAM2000®) of Plasma Donors for the Production of Vaccinia Immune Globulin Intravenous (VIGIV) Recruiting NCT02443623 Phase 4
4 The Clinical Study of Analgecine for the Treatment of Neuropathic Pain Completed NCT02633618 Phase 3
5 Vaccinia Vaccine (ACAM2000) for the Production of Vaccinia Immune Globulin Intravenous (VIGIV) Completed NCT01158157 Phase 3
6 A Randomized, Open-label Phase III Non-inferiority Trial to Compare Indicators of Efficacy for MVA-BN® Smallpox Vaccine to ACAM2000® in 18-42 Year Old Healthy Vaccinia-naïve Subjects Completed NCT01913353 Phase 3
7 A Phase 3 Randomized, Open-Label Study Comparing Pexa Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy Completed NCT02562755 Phase 3 Sorafenib
8 A Randomized, Double-Blind, Placebo-Controlled Phase III Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-Naïve Subjects Completed NCT01144637 Phase 3
9 An Open-label, Single Arm, Phase III Clinical Study to Evaluate the Efficacy and Safety of CJ Smallpox Vaccine in Vaccinia-naive Healthy Volunteers Completed NCT01056770 Phase 3 smallpox vaccine CJ-50300
10 A Randomized, Double-blind, Multicenter Phase III Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of a Freeze-dried Formulation of MVA-BN® Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects Completed NCT03699124 Phase 3
11 Evaluation of a Heterologous, Two-dose Preventive Ebola Vaccine for Effectiveness and Safety in the Democratic Republic of the Congo Active, not recruiting NCT04152486 Phase 3
13 A Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of LC16m8, A Modified Vaccinia Vaccine, in Healthy Volunteers Unknown status NCT00103584 Phase 1, Phase 2
14 A Phase 2b Randomized Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Sorafenib Treatment Completed NCT01387555 Phase 2
15 Comparison of the Safety and Immunogenicity of Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid Formulation IMVAMUNE® (1x10^8 TCID50) Administered by the Subcutaneous Route and a Lower Dose Liquid Formulation IMVAMUNE® (2x10^7 TCID50) Administered by the Intradermal Route in Healthy Vaccinia-Naïve Individuals Completed NCT00914732 Phase 2
16 Evaluation of IMVAMUNE® Smallpox Vaccine With Respect to Safety and Optimization of Immune Responses by Different Vaccination Regimens in Vaccinia-Naïve Adults Completed NCT00437021 Phase 1, Phase 2 Placebo (subcutaneous);Placebo (scarification)
17 Comparison of Safety and Immunogenicity of a High Dose (5 x 10^8 TCID50) and a Standard Dose (1 x 10^8 TCID50) of IMVAMUNE® in Healthy Vaccinia-Naive Individuals Completed NCT00879762 Phase 2 Placebo
18 Evaluation and Treatment of Ocular Complications of Vaccinia Vaccination: Suitability of NP-016 Vaccinia Immune Globulin (VIG) for Sight-Threatening Conditions [VIG31] Completed NCT00081835 Phase 2 NP-016 Vaccine Immune Globulin (IV-VIG)
19 ACAM 3000 MVA (Acambis Modified Vaccinia Ankara) Immunization Followed by Dryvax® Vaccination of Healthy Vaccinia-Naïve Adults: A Phase I/II, Placebo-Controlled Study of the Effects of Dose and Route of Administration of MVA on Safety, Reactogenicity and Immunogenicity, Followed by Dryvax® Immunization to Assess Effects of MVA Vaccination on Dryvax® Takes Completed NCT00133575 Phase 1, Phase 2
20 A Phase 1/2a Dose-escalation Study of JX 594 Administered by Multiple Intravenous (IV) Infusions Alone and in Combination With Irinotecan in Patients With Metastatic, Refractory Colorectal Carcinoma. Completed NCT01394939 Phase 1, Phase 2 Irinotecan
21 A Phase II Study of Neoadjuvant rFowlpox-PSA (L155)-TRICOM (Prostvac-F/TRICOM) in Combination With rVaccinia-PSA (L155)-TRICOM (Prostvac-V/TRICOM) in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy Completed NCT02153918 Phase 2
22 A Phase II Trial of Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer Completed NCT01875250 Phase 2 Enzalutamide (Xtandi)
23 Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection Completed NCT02038881 Phase 2
24 A Phase I/II, Open-Label Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intratumoral Injection in Patients With Unresectable Stage 3 or Stage 4 Malignant Melanoma Completed NCT00429312 Phase 1, Phase 2
25 An Open Label Pilot Study to Evaluate the Safety and Tolerability of PANVAC-V (Vaccinia) and PANVAC-F (Fowlpox) in Combination With Sargramostim in Adults With Metastatic Carcinoma Completed NCT00088413 Phase 1, Phase 2 Sargramostim (GM-CSF, Leukine)
26 A Randomized Phase II Trial Combining Vaccine Therapy With PROSTVAC/TRICOM and Flutamide vs. Flutamide Alone in Men With Androgen Insensitive, Non-Metastatic (D0.5) Prostate Cancer Completed NCT00450463 Phase 2 Sargramostim (GM-CSF, Leukine);Flutamide (Eulexin)
27 Phase I/II Study of Intraperitoneal Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Peritoneal Carcinomatosis Completed NCT01443260 Phase 1, Phase 2
28 A Phase II Study Evaluating the Safety and Immunogenicity of a New TB Vaccine, MVA85A, in Healthy Children and Infants After BCG Vaccination at Birth Completed NCT00679159 Phase 2
29 A Phase 2a Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of pGA2/JS7 DNA and MVA/HIV62, in Healthy, HIV Uninfected Vaccinia-naive Adult Participants Completed NCT00820846 Phase 2
30 A Phase I/II Study to Assess the Safety, Immunogenicity and Protective Efficacy of Novel Malaria Vaccine Candidates ChAdOx1 LS2 and MVA LS2 in Healthy UK Adults Completed NCT03203421 Phase 1, Phase 2
31 A Phase II-a, Open-Label, Randomized Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intratumoral Injection in Patients With Unresectable Primary Hepatocellular Carcinoma Completed NCT00554372 Phase 2
32 A Phase 2 Open-Label Pilot Safety Study of JX-594 (Vaccinia GM-CSF/Thymidine Kinase-Deactivated Virus) Administered by IV Infusion Followed by Intratumoral Injection Prior to Standard Sorafenib Treatment in Patients With Unresectable Primary Hepatocellular Carcinoma Completed NCT01171651 Phase 2 JX-594 followed by sorafenib
33 A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer Completed NCT00108732 Phase 2 Bicalutamide;Goserelin Acetate
34 A Phase I/II Study to Evaluate the Safety and Preliminary Efficacy of Various Concentrations of Aventis Pasteur's Smallpox Vaccine, USP (APSV) in Vaccinia-naive Adults Completed NCT00038987 Phase 1, Phase 2
35 Active Specific Intranodal Immunotherapy With a Recombinant Vaccinia Virus Expressing Three Melanoma Associated Epitopes and Two Costimulatory Molecules, Followed by Immunization With Synthetic Melanoma Associated Epitopes. A Phase I/II Trial in Patients With Stages IIb to IV Melanoma Completed NCT00116597 Phase 1, Phase 2
36 A Multicenter, Double-Blind, Randomized Study of the Safety and Efficacy of Aventis Pasteur's Smallpox Vaccine, USP (APSV) in Vaccinia-Naive Adults. Completed NCT00050518 Phase 2
37 Phase IIa Study of AIDS Vaccine (Combined Use of DNA Vaccine and Recombinant Vaccinia Virus Tiantan) Completed NCT01705223 Phase 2
38 A Randomized, Double-blind, Multicenter Phase II Trial to Compare the Immunogenicity and Safety of a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects Completed NCT01668537 Phase 2
39 A Single-Arm, Open-Label Phase 2 Study of JX 594 (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) Administered by Weekly Intravenous (IV) Infusions in Sorafenib-naïve Patients With Advanced Hepatocellular Carcinoma (HCC) Completed NCT01636284 Phase 2
40 A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects Completed NCT00857493 Phase 2
41 Phase II Study of Recombinant Vaccinia-NY-ESO-1 (rV-NY-ESO-1) and Recombinant Fowlpox-NY-ESO-1 (rF-NY-ESO-1) in Patients With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen Completed NCT00112957 Phase 2
42 Treatment Of Patients With Metastatic Melanoma Using Recombinant Vaccinia And Fowlpox Viruses Encoding The Tyrosine Antigen In Combination With Interleukin-2 Completed NCT00054535 Phase 2
43 A Phase II Trial in Patients With Early Cervical Cancer to Study The Safety and The Immunological Effects of Vaccination With TA-HPV, A Live Recombinant Vaccinia Virus Expressing The Human Papilloma Virus 16 and 18 E6 and E7 Proteins Completed NCT00002916 Phase 2
44 A Pilot Study of Sequential Vaccinations With ALVAC-CEA and Vaccinia-CEA With the Addition of IL-2 and GM-CSF in Patients With CEA Expressing Tumors Completed NCT00003125 Phase 2
45 A Comparison of Dressing Preparations for Smallpox Vaccination Sites With a Focus Upon the Risk of Secondary Transmission of Vaccinia Virus Completed NCT00063856 Phase 1, Phase 2
46 Immunization of Patients With Metastatic Melanoma Using Recombinant Fowlpox and Vaccinia Viruses Encoding the Tyrosinase Antigen Completed NCT00019734 Phase 2
47 A Randomized Pilot Phase II Study of Docetaxel Alone or in Combination With PANVAC(Trademark)-V (Vaccinia) and PANVAC(Trademark)-F (Fowlpox) in Adults With Metastatic Breast Cancer Completed NCT00179309 Phase 2 Docetaxel
48 Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2 Study Assessing Safety, Tolerability, Immunogenicity of Three Dose Levels of ACAM3000 Modified Vaccinia Ankara Smallpox Vaccine in Adults With and Without Previous Smallpox Vaccination Completed NCT00466245 Phase 2 MVA Smallpox vaccine;Placebo
49 A Pilot Study Of Sequential Vaccinations With Recombinant Vaccinia-CEA(6D)-TRICOM, And Recombinant Fowlpox-CEA(6D)-TRICOM (B7.1/ICIAM-1/LFA-3) With Sargramostim (GM-CSF), In Conjunction With Standard Adjuvant Chemotherapy In High Risk Breast Cancer Patients Status Post Surgery With 4+ Or More Lymph Nodes And CEA Expressing Tumors Completed NCT00052351 Phase 2 cyclophosphamide;doxorubicin hydrochloride;paclitaxel
50 A Combined Phase 1/2a, Exploratory Study of a Therapeutic Vaccine Using an Adenovirus Type 26 Vector Prime and Modified Vaccinia Ankara Boost Combination With Mosaic Inserts in HIV-1 Infected Adults Who Initiated Antiretroviral Treatment During Acute HIV Infection Completed NCT02919306 Phase 1, Phase 2 Placebo

Search NIH Clinical Center for Vaccinia

Cochrane evidence based reviews: vaccinia

Genetic Tests for Vaccinia

Anatomical Context for Vaccinia

The Foundational Model of Anatomy Ontology organs/tissues related to Vaccinia:


MalaCards organs/tissues related to Vaccinia:

T Cells, Prostate, B Cells, Brain, Colon, Bone Marrow, Spleen

Publications for Vaccinia

Articles related to Vaccinia:

(show top 50) (show all 13532)
# Title Authors PMID Year
A novel vaccinia virus enhances anti-tumor efficacy and promotes a long-term anti-tumor response in a murine model of colorectal cancer. 61
33575472 2021
Application of real-time PCR to significantly reduce the time to obtain recombinant MVA virus. 61
33359615 2021
Using an effective TB vaccination regimen to identify immune responses associated with protection in the murine model. 61
33549390 2021
Vaccinia virus-based vector against infectious diseases and tumors. 61
33606578 2021
(+)-Camphor and (-)-borneol derivatives as potential anti-orthopoxvirus agents. 61
33605479 2021
A class of viral inducer of degradation of the necroptosis adaptor RIPK3 regulates virus-induced inflammation. 61
33444549 2021
Recent Advances in Systemic Therapies for Advanced Hepatocellular Carcinoma. 61
33552839 2021
Fighting Fire With Fire: Oncolytic Virotherapy for Thoracic Malignancies. 61
33575873 2021
Localized and Systemic Immune Responses against SARS-CoV-2 Following Mucosal Immunization. 61
33562141 2021
Intratumoral virotherapy with 4-1BBL armed modified vaccinia Ankara eradicates solid tumors and promotes protective immune memory. 61
33579736 2021
Viral growth factor- and STAT3 signaling-dependent elevation of the TCA cycle intermediate levels during vaccinia virus infection. 61
33529218 2021
Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT). 61
33581644 2021
Vaccinia Virus Infection Inhibits Skin Dendritic Cell Migration to the Draining Lymph Node. 61
33419767 2021
Randomized Trial of a Vaccine Regimen to Prevent Chronic HCV Infection. 61
33567193 2021
A highly attenuated vaccinia virus strain LC16m8-based vaccine for severe fever with thrombocytopenia syndrome. 61
33534867 2021
Live Vaccinia Virus-Coated Microneedle Array Patches for Smallpox Vaccination and Stockpiling. 61
33546332 2021
IL-36γ-armed oncolytic virus exerts superior efficacy through induction of potent adaptive antitumor immunity. 61
33538860 2021
In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity. 61
33608375 2021
Modeling and characterization of inter-individual variability in CD8 T cell responses in mice. 61
33554899 2021
Epicutaneous immunization with modified vaccinia Ankara viral vectors generates superior T cell immunity against a respiratory viral challenge. 61
33398010 2021
MVA Vector Vaccines Inhibit SARS CoV-2 Replication in Upper and Lower Respiratory Tracts of Transgenic Mice and Prevent Lethal Disease. 61
33442693 2021
Orthopoxvirus K3 orthologs show virus- and host-specific inhibition of the antiviral protein kinase PKR. 61
33444388 2021
Subversion of Programed Cell Death by Poxviruses. 61
33507400 2021
A Review of Piezoelectric and Magnetostrictive Biosensor Materials for Detection of COVID-19 and Other Viruses. 61
33230875 2021
The European tiered approach for virucidal efficacy testing - rationale for rapidly selecting disinfectants against emerging and re-emerging viral diseases. 61
33478622 2021
Neurotropin exerts neuroprotective effects after spinal cord injury by inhibiting apoptosis and modulating cytokines. 61
33437626 2021
Beclin1‑armed oncolytic Vaccinia virus enhances the therapeutic efficacy of R‑CHOP against lymphoma in vitro and in vivo. 61
33469679 2021
CD8 T Cells Show Protection against Highly Pathogenic Simian Immunodeficiency Virus (SIV) after Vaccination with SIV Gene-Expressing BCG Prime and Vaccinia Virus/Sendai Virus Vector Boosts. 61
33087465 2021
A systemically deliverable Vaccinia virus with increased capacity for intertumoral and intratumoral spread effectively treats pancreatic cancer. 61
33500259 2021
Improving Immunoassay Performance with Cleavable Blocking of Microarrays. 61
33305941 2021
NMR assignments of vaccinia virus protein A28: an entry-fusion complex component. 61
33398629 2021
Loss of the vaccinia virus 35-amino acid hydrophobic O3 protein is partially compensated by mutations in the transmembrane domains of other entry proteins. 61
33504600 2021
Influenza- and MCMV-induced memory CD8 T cells control respiratory vaccinia virus infection despite residence in distinct anatomical niches. 61
33479479 2021
The Vaccinia Virus B12 Pseudokinase Represses Viral Replication via Interaction with the Cellular Kinase VRK1 and Activation of the Antiviral Effector BAF. 61
33177193 2021
IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy. 61
33504576 2021
Vaccinia Virus Protein B18R: Influence on mRNA Immunogenicity and Translation upon Non-Viral Delivery in Different Ocular Cell Types. 61
33430462 2021
Safety, biodistribution and viral shedding of oncolytic vaccinia virus TG6002 administered intravenously in healthy beagle dogs. 61
33500518 2021
Genomic diversity of vaccinia virus strain Cantagalo isolated in southeastern Brazil during the early years of the outbreak, 1999-2006. 61
33566940 2021
COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice. 61
33414159 2021
Injection site vaccinology of a recombinant vaccinia-based vector reveals diverse innate immune signatures. 61
33439897 2021
Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody. 61
33468698 2021
Exploring the Pivotal Immunomodulatory and Anti-Inflammatory Potentials of Glycyrrhizic and Glycyrrhetinic Acids. 61
33505216 2021
Preoperative medications is one of the factor affecting patient-reported outcomes after total hip arthroplasty. 61
33424189 2021
Analysis of SEC-SAXS data via EFA deconvolution and Scatter. 61
33586708 2021
Durable natural killer cell responses after heterologous two-dose Ebola vaccination. 61
33514756 2021
mSphere of Influence: Apoptotic Mimicry and Virus Entry. 61
33504657 2021
Here, There, and Everywhere: The Wide Host Range and Geographic Distribution of Zoonotic Orthopoxviruses. 61
33396609 2020
Integrated analysis of DNA methylation and gene expression profiles identified S100A9 as a potential biomarker in ulcerative colitis. 61
33185247 2020
Mucosal IL-4R antagonist HIV vaccination with SOSIP-gp140 booster can induce high-quality cytotoxic CD4+/CD8+ T cells and humoral responses in macaques. 61
33328567 2020
Intrapleural interleukin-2-expressing oncolytic virotherapy enhances acute antitumor effects and T-cell receptor diversity in malignant pleural disease. 61
33485667 2020

Variations for Vaccinia

Expression for Vaccinia

Search GEO for disease gene expression data for Vaccinia.

Pathways for Vaccinia

GO Terms for Vaccinia

Cellular components related to Vaccinia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.4 WASHC2C VRK1 NLRP1 ITSN1 IRF3 EPS15

Biological processes related to Vaccinia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 defense response to virus GO:0051607 9.46 NLRP1 IRF3 IFNA1 EIF2AK2
2 dendritic cell differentiation GO:0097028 9.32 CSF2 AZI2
3 viral process GO:0016032 9.32 VRK2 NLRP1 ITSN1 IRF3 EPS15 EIF2AK2
4 mitotic nuclear envelope reassembly GO:0007084 9.26 VRK1 BANF1
5 protein autophosphorylation GO:0046777 9.26 VRK2 VRK1 EIF2S1 EIF2AK2

Molecular functions related to Vaccinia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.6 WASHC2C VRK3 VRK2 VRK1 NLRP1 ITSN1

Sources for Vaccinia

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....